• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Overlooked Cornerstone in Precise Medicine: Personalized Postoperative Surveillance Plan for NSCLC.精准医学中被忽视的基石:非小细胞肺癌的个性化术后监测计划
JTO Clin Res Rep. 2024 Jun 27;5(8):100701. doi: 10.1016/j.jtocrr.2024.100701. eCollection 2024 Aug.
2
Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.根治性治疗非小细胞肺癌(NSCLC)后随访对新发和复发病灶、再治疗和生存的影响:系统评价和荟萃分析。
J Thorac Oncol. 2021 May;16(5):784-797. doi: 10.1016/j.jtho.2021.01.1622. Epub 2021 Feb 12.
3
Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.针对接受根治性治疗的非小细胞肺癌患者,采用个体化、肿瘤相关的循环肿瘤 DNA 检测方法进行微小残留病灶检测。
Thorac Cancer. 2024 May;15(13):1095-1102. doi: 10.1111/1759-7714.15281. Epub 2024 Apr 1.
4
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.循环肿瘤 DNA(ctDNA)在非小细胞肺癌中的作用研究。
Int J Mol Sci. 2022 Aug 12;23(16):9006. doi: 10.3390/ijms23169006.
5
Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.根治性治疗后肺癌患者的随访和监测:肺癌的诊断和管理,第 3 版:美国胸科医师学会循证临床实践指南。
Chest. 2013 May;143(5 Suppl):e437S-e454S. doi: 10.1378/chest.12-2365.
6
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.治疗后残留 ctDNA 可预测早期非小细胞肺癌患者的早期复发。
Ann Oncol. 2022 May;33(5):500-510. doi: 10.1016/j.annonc.2022.02.007. Epub 2022 Mar 17.
7
Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.PET/CT监测对Ⅲ期非小细胞肺癌根治性放疗后早期复发检测的影响
Clin Lung Cancer. 2017 Mar;18(2):141-148. doi: 10.1016/j.cllc.2016.11.003. Epub 2016 Nov 10.
8
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.通过对血浆游离DNA进行超深度测序检测循环肿瘤DNA,用于监测早期肺癌的微小残留病和复发的早期检测。
Cancer. 2024 May 15;130(10):1758-1765. doi: 10.1002/cncr.35263. Epub 2024 Feb 29.
9
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review.液体活检基因分型在肺癌中的临床应用与价值:综述
Lung Cancer (Auckl). 2023 Feb 3;14:11-25. doi: 10.2147/LCTT.S388047. eCollection 2023.
10
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.根治性治疗后肺癌监测:ASCO 指南。
J Clin Oncol. 2020 Mar 1;38(7):753-766. doi: 10.1200/JCO.19.02748. Epub 2019 Dec 12.

本文引用的文献

1
A randomized phase III trial of postoperative surveillance for pathological stage II and IIIA non-small cell lung cancer (JCOG2012, PHOENIX).日本癌症研究集团(JCOG)2012 年开展的一项术后病理 II 期和 IIIA 期非小细胞肺癌(PHOENIX)术后监测的随机 III 期临床试验。
Jpn J Clin Oncol. 2024 Aug 14;54(8):926-929. doi: 10.1093/jjco/hyae056.
2
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.切除的肺腺癌中 KRAS G12D 突变患者的临床病理特征、同时存在的基因组改变和临床结局。
Eur J Cancer. 2024 May;202:113985. doi: 10.1016/j.ejca.2024.113985. Epub 2024 Mar 2.
3
The landscape of cancer research and cancer care in China.中国癌症研究与癌症护理的现状
Nat Med. 2023 Dec;29(12):3022-3032. doi: 10.1038/s41591-023-02655-3. Epub 2023 Dec 12.
4
Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.根据分期和影像学特征分层的KRAS G12C突变在肺腺癌中的预后价值。
J Thorac Cardiovasc Surg. 2023 Dec;166(6):e479-e499. doi: 10.1016/j.jtcvs.2023.04.037. Epub 2023 May 2.
5
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.使用 ctDNA 追踪 TRACERx 中的早期肺癌转移扩散。
Nature. 2023 Apr;616(7957):553-562. doi: 10.1038/s41586-023-05776-4. Epub 2023 Apr 13.
6
The evolution of non-small cell lung cancer metastases in TRACERx.TRACERx 中观察到的非小细胞肺癌转移演变。
Nature. 2023 Apr;616(7957):534-542. doi: 10.1038/s41586-023-05729-x. Epub 2023 Apr 12.
7
Recurrence Patterns and Patient Outcomes in Resected Lung Adenocarcinoma Differ according to Ground-Glass Opacity at CT.CT 显示磨玻璃密度的肺腺癌切除术后复发模式和患者结局存在差异。
Radiology. 2023 May;307(3):e222422. doi: 10.1148/radiol.222422. Epub 2023 Mar 21.
8
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.肺内磨玻璃密度结节直径≤3cm 包括磨玻璃成分的肺癌行局部切除术(JCOG1211):一项多中心、单臂、阳性、III 期临床试验
Lancet Respir Med. 2023 Jun;11(6):540-549. doi: 10.1016/S2213-2600(23)00041-3. Epub 2023 Mar 6.
9
Ten-Year Follow-up Results of Pure Ground-Glass Opacity-Featured Lung Adenocarcinomas After Surgery.纯磨玻璃密度型肺腺癌手术后十年随访结果。
Ann Thorac Surg. 2023 Aug;116(2):230-237. doi: 10.1016/j.athoracsur.2023.01.014. Epub 2023 Jan 13.
10
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.

精准医学中被忽视的基石:非小细胞肺癌的个性化术后监测计划

The Overlooked Cornerstone in Precise Medicine: Personalized Postoperative Surveillance Plan for NSCLC.

作者信息

Jiang Chenyu, Zhang Yang, Deng Penghao, Lin Han, Fu Fangqiu, Deng Chaoqiang, Chen Haiquan

机构信息

Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

Institute of Thoracic Oncology, Fudan University, Shanghai, People's Republic of China.

出版信息

JTO Clin Res Rep. 2024 Jun 27;5(8):100701. doi: 10.1016/j.jtocrr.2024.100701. eCollection 2024 Aug.

DOI:10.1016/j.jtocrr.2024.100701
PMID:39188582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11345377/
Abstract

Non-small cell lung cancer recurrence after curative-intent surgery remains a challenge despite advancements in treatment. We review postoperative surveillance strategies and their impact on overall survival, highlighting recommendations from clinical guidelines and controversies. Studies suggest no clear benefit from more intensive imaging, whereas computed tomography scans reveal promise in detecting recurrence. For early-stage disease, including ground-glass opacities and adenocarcinoma in situ or minimally invasive adenocarcinoma, less frequent surveillance may suffice owing to favorable prognosis. Liquid biopsy, especially circulating tumor deoxyribonucleic acid, holds potential for detecting minimal residual disease. Clinicopathologic factors and genomic profiles can also provide information about site-specific metastases. Machine learning may enable personalized surveillance plans on the basis of multi-omics data. Although precision medicine transforms non-small cell lung cancer treatment, optimizing surveillance strategies remains essential. Tailored surveillance strategies and emerging technologies may enhance early detection and improve patients' survival, necessitating further research for evidence-based protocols.

摘要

尽管治疗方面取得了进展,但根治性手术后非小细胞肺癌的复发仍然是一个挑战。我们回顾了术后监测策略及其对总生存期的影响,重点介绍了临床指南中的建议和争议。研究表明,更密集的影像学检查没有明显益处,而计算机断层扫描在检测复发方面显示出前景。对于早期疾病,包括磨玻璃影、原位腺癌或微浸润腺癌,由于预后良好,较少频率的监测可能就足够了。液体活检,尤其是循环肿瘤脱氧核糖核酸,在检测微小残留病方面具有潜力。临床病理因素和基因组图谱也可以提供有关特定部位转移的信息。机器学习可能基于多组学数据实现个性化监测计划。尽管精准医学改变了非小细胞肺癌的治疗方式,但优化监测策略仍然至关重要。量身定制的监测策略和新兴技术可能会加强早期检测并提高患者生存率,因此需要进一步研究以制定基于证据的方案。